ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
methodsUsing the WHO pharmacovigilance database, we identified cases using the Medical Dictionary for Regulatory Activities Preferred Term "Raynaud's phenomenon," and we excluded all Individual Case Safety Reports (ICSRs) associated with at least one drug used in RP treatment. To estimate signals of disproportionate reporting (SDR), we calculated information component (IC) values (IC
resultsWe included 4,430 ICSRs of RP in our analysis. We found 124 significant SDRs in the primary analysis, of which 52 SDRs were consistent across all sensitivity analyses, and 16 were considered probable after signal evaluation and prioritization, including amphetamine-like, antimigraine drugs, antineoplastics drugs, and dopaminergic agonists. Most of the targets involved were 5-HT1A receptors, sodium-dependent noradrenaline transporters, and beta-1 and beta-2 adrenergic receptors. Cluster analyses yielded inconsistent results according to the method used.
conclusionThis study allowed us to identify robust safety signals (such as solriamfetol, tyrosine kinase inhibitors, and calcitonin gene-related peptide inhibitors) for drugs associated with RP and potential implicated pathophysiologic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.